CD32B

Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA

Retrieved on: 
Thursday, January 6, 2022

The potential approval of margetuximab will also be an important addition to our growing womens oncology franchise and marks Zai Labs sixth NDA acceptance by the NMPA.

Key Points: 
  • The potential approval of margetuximab will also be an important addition to our growing womens oncology franchise and marks Zai Labs sixth NDA acceptance by the NMPA.
  • Zai Labs bridging study confirmed the clinical benefit of margetuximab in Chinese patients.
  • We are excited to see this potential new treatment option for patients living with metastatic breast cancer in China."
  • Breast cancer is the most common cancer in Chinese women, with 416,371 newly diagnosed cases and 117,174 deaths in 20201.

Provention Bio Appoints Jan Hillson, M.D., as Senior Vice President of Clinical Development

Retrieved on: 
Wednesday, November 17, 2021

RED BANK, N.J., Nov. 17, 2021 /PRNewswire/ --Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Jan Hillson, M.D., as Senior Vice President of Clinical Development.

Key Points: 
  • RED BANK, N.J., Nov. 17, 2021 /PRNewswire/ --Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Jan Hillson, M.D., as Senior Vice President of Clinical Development.
  • Dr. Hillson was most recently Senior Vice President, Clinical Development at Alpine Immune Sciences.
  • Dr. Hillson also served as Senior Vice Presidentof Clinical and Translational Research at ChemoCentryx.
  • As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products.

CASI Pharmaceuticals Partner, BioInvent, To Present Further Positive Clinical Data On BI-1206 At ASH 2021

Retrieved on: 
Friday, November 5, 2021

The latest data will be published in a poster at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021) in December 2021.

Key Points: 
  • The latest data will be published in a poster at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021) in December 2021.
  • The data were obtained from the dose-escalation phase of the trial up to July 2021 (the ASH abstract cut-off date).
  • ASH 2021 will take place on December 1114, 2021, at the Georgia World Congress Center - Atlanta, GA, and virtually.
  • The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., which is located in Beijing, China.